| Literature DB >> 19442851 |
Madisa Mine1, Keabetswe Bedi, Talkmore Maruta, Dignity Madziva, Modiri Tau, Tatenda Zana, Tendani Gaolathe, Sikhulile Moyo, Khumo Seipone, Ndwapi Ndwapi, Max Essex, Richard Marlink.
Abstract
Roche COBAS Amplicor monitor version 1.5 assay is considered gold standard for viral load monitoring in Botswana. Due to its demand for elaborate infrastructure, viral load testing has been confined to the national HIV reference laboratories. Cavidi ExaVir Load version 2 assay was considered as a potential alternative to decentralize viral load testing to the rural/remote hospital laboratories and thus increase access to therapy. This study compared the performance of ExaVir Load v2 assay at a district hospital laboratory in Serowe and COBAS Amplicor monitor v1.5 assay at the Botswana Harvard HIV Reference Laboratory using quality assessment samples and plasma from HIV-positive individuals. ExaVir Load v2 and COBAS Amplicor monitor v1.5 assays had very good agreement; Kappa statistic 0.951. The COBAS Amplicor monitor v1.5 and ExaVir Load v2 assays detected HIV-1 RNA in 84 and 86 samples but did not detect HIV-1 RNA in 221 and 219 samples, respectively. The two assays detected HIV-1 RNA concordantly in 82 samples and were strongly correlated (r=0.8554, P<0.0001). ExaVir Load v2 assay provided a simple and reliable alternative viral load system that is adaptable to district hospital laboratories. The cost per test is less than RT-PCR. The ExaVir Load v2 systems have since been placed in four more district and primary hospital laboratories.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19442851 DOI： 10.1016/j.jviromet.2009.03.008
Source DB: PubMed Journal: J Virol Methods ISSN： 0166-0934 Impact factor: 2.014